ARMP Key Statistics, Chart & Performance
The current stock price of ARMP is 5.8872 USD. In the past month the price decreased by -13.75%. In the past year, price increased by 163.25%.
ARMP Latest News, Press Relases and Analysis
ARMP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.57 | 393.64B | ||
| AMGN | AMGEN INC | 14.57 | 171.54B | ||
| GILD | GILEAD SCIENCES INC | 15.06 | 153.03B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.9 | 114.10B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.93B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.2 | 52.43B | ||
| INSM | INSMED INC | N/A | 41.24B | ||
| NTRA | NATERA INC | N/A | 31.53B | ||
| BIIB | BIOGEN INC | 10.32 | 25.33B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.58 | 21.11B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B | ||
| INCY | INCYTE CORP | 14.83 | 18.69B |
Related stock screener links
About ARMP
Company Profile
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 60 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Company Info
ARMATA PHARMACEUTICALS INC
5005 Mcconnell Ave
Los Angeles CALIFORNIA 90292 US
CEO: Todd R. Patrick
Employees: 60
Phone: 13106652928
ARMATA PHARMACEUTICALS INC / ARMP FAQ
What does ARMATA PHARMACEUTICALS INC do?
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 60 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
What is the stock price of ARMATA PHARMACEUTICALS INC today?
The current stock price of ARMP is 5.8872 USD. The price increased by 2.03% in the last trading session.
Does ARMATA PHARMACEUTICALS INC pay dividends?
ARMP does not pay a dividend.
What is the ChartMill rating of ARMATA PHARMACEUTICALS INC stock?
ARMP has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting ARMP stock to perform?
7 analysts have analysed ARMP and the average price target is 9.18 USD. This implies a price increase of 55.93% is expected in the next year compared to the current price of 5.8872.
Should I buy ARMP stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ARMP.
Can you provide the upcoming earnings date for ARMATA PHARMACEUTICALS INC?
ARMATA PHARMACEUTICALS INC (ARMP) will report earnings on 2026-03-18, after the market close.
ARMP Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ARMP. When comparing the yearly performance of all stocks, ARMP is one of the better performing stocks in the market, outperforming 97.87% of all stocks.
ARMP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ARMP. ARMP may be in some trouble as it scores bad on both profitability and health.
ARMP Financial Highlights
Over the last trailing twelve months ARMP reported a non-GAAP Earnings per Share(EPS) of -1.32. The EPS decreased by -15.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ARMP Forecast & Estimates
7 analysts have analysed ARMP and the average price target is 9.18 USD. This implies a price increase of 55.93% is expected in the next year compared to the current price of 5.8872.
For the next year, analysts expect an EPS growth of -202.08% and a revenue growth -3.64% for ARMP